We are developing a human-derived anti-nuclear antibody (ANA) that targets areas of necrosis present in many types of tumors. The versatility of our drug delivery platforms allow us to focus on under served rare/pediatric cancers.

NanoSmart's mission is to positively impact patients with cancer and other diseases worldwide by improving the safety and efficacy of existing pharmaceutical products.

Our tumor-targeting technology enables the creation of a broad product pipeline and gives us the ability to pursue co-development opportunities with industry to deliver new or improved therapies for a wide variety of diseases.

NanoSmart has completed its targeting antibody and various lipid nanoparticle delivery platforms, secured its intellectual property, acquired multiple orphan drug designations, and initiated development of targeted nanoparticl formulations of various APIs.